Satish Velagapudi, MD
Urology · Fort Wayne, INNPI 1831100015
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,253 of the $1,986 with a category attached, or 63.1%. Biotronik Inc. accounts for 78.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,526 and has fallen 88.3% since, to $178 in 2025. That places this record below the midpoint for urology clinicians in IN, where the typical reported total is $3,350.
Across 22 payments — averaging $90.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$2K
- Procept Biorobotics Corporation$119
- Astellas Pharma US Inc$68
- Pfizer$42
- Novartis$42
- Urogen Pharma, Inc.$36
- plus $125 from 6 others
What the payments were for
- Travel & lodging$1,25363%
- Food & beverage$66534%
- Education$683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 6 | $1,553 |
| Procept Biorobotics Corporation | 1 | $119 |
| Astellas Pharma US Inc | 1 | $68 |
| Pfizer | 3 | $42 |
| Novartis | 2 | $42 |
| Urogen Pharma, Inc. | 1 | $36 |
| EDAP Technomed Inc | 3 | $33 |
| Olympus America Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
| Ambu Inc. | 1 | $15 |
| Calyxo, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rivacor 7 DR-T$309
- AquaBeam Robotic System$119
- BioMonitor$105
How this compares
$1,986 in reported general payments places this provider in the 35th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 164 | $131,044 |
| GemtesaVibegron | 71 | $67,457 |
| Tamsulosin Hcl | 1,523 | $21,016 |
| Finasteride | 1,056 | $11,594 |
| Potassium Citrate ErPotassium Citrate | 60 | $7,440 |
| Dutasteride | 173 | $5,234 |
| Silodosin | 53 | $4,955 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 245 | $4,685 |
| Tadalafil | 11 | $2,951 |
| Testosterone Cypionate | 47 | $2,148 |
| Potassium Chloride | 55 | $1,977 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $1,617 |
| Oxybutynin Chloride | 50 | $1,480 |
| Terazosin Hcl | 105 | $1,098 |
| Solifenacin Succinate | 33 | $1,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $68 | $131,044164 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $67,45771 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 272 urology providers in Indiana.
Other urology in Fort Wayne
- Colin LinkeFort Wayne$65K
- Mark DabagiaFort Wayne$27K
- Jorge ArzolaFort Wayne$19K
- George MartinFort Wayne$16K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.